Monogram Technologies (Monogram Technologies) Risk Assessment

View and export this data going back to 2023. Start your Free Trial

What is Monogram Technologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Monogram Technologies is: No Data: Cannot be evaluated.

Competitive Comparison of Monogram Technologies's Risk Assessment

For the Medical Devices subindustry, Monogram Technologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Monogram Technologies's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Monogram Technologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Monogram Technologies's Risk Assessment falls into.

Monogram Technologies (NAS:MGRM) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Monogram Technologies Risk Assessment Related Terms

Thank you for viewing the detailed overview of Monogram Technologies's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Monogram Technologies (Monogram Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Monogram Technologies Inc (NAS:MGRM) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

J7J:Germany

Address

3913 Todd Lane, Suite 307, Austin, TX, USA, 78744

Website

https://www.monogramorthopedics.com

Monogram Orthopaedics Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.

Executives

Paul H Riss	director
Noel Knape	officer: Chief Financial Officer	3913 TODD LANE, AUSTIN TX 78744
Benjamin Sexson	director, 10 percent owner, officer: Chief Executive Officer	3913 TODD LANE, AUSTIN TX 78744
Noel Goddard	director	3913 TODD LANE, AUSTIN TX 78744
Kamran Shamaei	officer: Chief Technology Officer	3913 TODD LANE, AUSTIN TX 78744
Douglas Unis	director	3913 TODD LANE, AUSTIN TX 78744